Compare Adaptive Biotechnologies Corp (ADPT) vs Nerdwallet Inc (NRDS) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

NRDS trades at $9.50, up 0.32% today, with a bullish technical signal from moving averages but overbought short-term RSI readings. The company shows strong fundamental improvement, with revenue growing from $539M in 2022 to $837M in 2025 and net income turning positive to $48.7M. Recent quarters have consistently beaten EPS estimates, and analyst consensus is a Buy with a $12.75 target, implying 34% upside. Positive news highlights the company's pivot to higher-margin transactions and resilience amid search headwinds.

The outlook is positive given strong earnings beats, robust cash flow, and attractive valuation multiples like a P/E of 10.19. Key risks include reliance on search traffic, competitive pressures, and projected negative net cash flow in 2026. Institutional sentiment is bullish, but investors should monitor execution on growth initiatives and macroeconomic impacts on consumer finance behavior.